Inside Drug Pricing

Trump’s CMS Secures Steeper MFPs For Second Round Of Negotiated Drugs

By Gabrielle Wanneh / November 30, 2025 at 11:13 PM

The newly announced maximum fair prices for Part D drugs in the second cycle of drug price negotiations range from a 38% cut to the price Medicare will pay for Teva Pharmaceuticals’ Huntington’s disease drugs to an 85% cut to the price of Merck’s type 2 diabetes treatments.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

Trump’s CMS Secures Steeper MFPs For Second Round Of Negotiated Drugs

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.